Pharvaris N.V. (PHVS) Financial Ratios
7 years of historical data (2018–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
5.17
↑+82% vs avg
5yr avg: 2.83
30Y Low2.1·High3.9
ROE
↑
-41.2%
-2% vs avg
5yr avg: -40.5%
30Y Low-87%·High-28%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
PHVS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Pharvaris N.V. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.0B | $1.0B | $1.1B | $378M | $438M | — | — | — |
| Enterprise Value | $1.6B | $756M | $686M | $216M | $229M | — | — | — |
| P/E Ratio → | -10.33 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — |
| P/B Ratio | 5.17 | 3.87 | 2.80 | 2.53 | 2.14 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
PHVS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
PHVS Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -41.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| ROE | -41.2% | -41.2% | -37.8% | -43.1% | -28.4% | -51.8% | -76.1% | -87.1% |
| ROA | -38.9% | -38.9% | -35.6% | -40.2% | -27.3% | -48.7% | -69.0% | -79.4% |
| ROIC | — | — | — | — | — | — | — | — |
| ROCE | -44.7% | -44.7% | -36.3% | -48.9% | -36.0% | -49.8% | -75.9% | -87.1% |
PHVS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $281M exceeds total debt of $861470, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.05 | -1.02 | -1.08 | -1.02 | -1.03 | -1.09 | -1.09 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | -5384.33 | -194.62 | -308.28 | — | — |
Net cash position: cash ($281M) exceeds total debt ($861470)
PHVS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Pharvaris N.V.'s current ratio of 12.60x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 9.16x to 12.60x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.60 | 12.60 | 27.25 | 9.16 | 30.28 | 19.00 | 10.70 | 11.29 |
| Quick Ratio | 12.60 | 12.60 | 27.25 | 8.93 | 30.28 | 19.00 | 10.70 | 11.29 |
| Cash Ratio | 12.22 | 12.22 | 26.79 | 8.88 | 29.97 | 18.56 | 10.56 | 11.19 |
| Asset Turnover | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
PHVS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Pharvaris N.V. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $54M | $38M | $34M | $30M | $31M | $32M | $32M |
Peer Comparison
Compare PHVS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 PHVSYou | $2B | -10.3 | — | — | — | — | -41.2% | — | — |
 KALV | $1B | -7.2 | — | — | — | — | -121.5% | -152.3% | — |
 BCAB | $5M | -0.1 | — | — | 100.0% | -2965.3% | — | — | — |
 PRAX | $8B | -25.1 | — | — | — | — | -45.8% | -65.0% | — |
 ARDX | $2B | -27.3 | — | — | 89.5% | -10.1% | -36.2% | -10.7% | — |
 IONS | $13B | -32.3 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 AKRO | $4B | -14.6 | — | — | — | — | -39.2% | -55.3% | — |
 CGEM | $903M | -4.0 | — | — | — | — | -44.0% | -43.5% | — |
 IQV | $30B | 22.5 | 12.9 | 14.6 | 26.3% | 14.0% | 21.4% | 8.7% | 4.7 |
 CRL | $9B | -62.5 | 13.0 | 17.3 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
 MEDP | $12B | 27.9 | 21.2 | 17.9 | 30.1% | 21.1% | 70.2% | 154.9% | 0.4 |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See PHVS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PHVS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PHVS vs KALV
Side-by-side business, growth, and profitability comparison vs KalVista Pharmaceuticals, Inc..
Start ComparisonPHVS — Frequently Asked Questions
Quick answers to the most common questions about buying PHVS stock.
What is Pharvaris N.V.'s P/E ratio?
Pharvaris N.V.'s current P/E ratio is -10.3x. This places it at the 50th percentile of its historical range.
What is Pharvaris N.V.'s ROE?
Pharvaris N.V.'s return on equity (ROE) is -41.2%. The historical average is -52.2%.
Is PHVS stock overvalued?
Based on historical data, Pharvaris N.V. is trading at a P/E of -10.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.